scholarly journals Acute Hepatitis Induced by Lyprinol, the Lipid Extract of the Green-Lipped Mussel (Perna canaliculus), in a Patient with Polyarthrosis

2012 ◽  
Vol 2012 ◽  
pp. 1-2 ◽  
Author(s):  
Amr Abdulazim ◽  
Marion Hädrich ◽  
Matteo Montani ◽  
Nasser Semmo
Keyword(s):  
Rheumatoid Arthritis ◽  
Abdominal Pain ◽  
Side Effects ◽  
Acute Hepatitis ◽  
Lipid Extract ◽  
Complementary Treatment ◽  
Perna Canaliculus ◽  
Liver Transaminases ◽  
Supplementary Treatment ◽  
Anti Inflammatory

Lyprinol, the lipid extract of the green-lipped mussel (Perna canaliculus), is a readily and freely available agent with a putative anti-inflammatory impact. It has already found application as a complementary and supplementary treatment of osteoarthritis, rheumatoid arthritis, asthma, and cancer. So far no major side effects for Lyprinol have been reported, yet. Here, we present the case of a 76-year-old woman with acutely exacerbating abdominal pain and highly elevated liver transaminases while taking Lyprinol as a complementary treatment of polyarthrosis.

scholarly journals Homology Modeling and Optimized Expression of Truncated IK Protein, tIK, as an Anti-Inflammatory Peptide

Molecules ◽  
2020 ◽  
Vol 25 (19) ◽  
pp. 4358
Author(s):  
Yuyoung Song ◽  
Minseon Kim ◽  
Yongae Kim
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Homology Modeling ◽  
Protein A ◽  
Interleukin 10 ◽  
Current Treatment ◽  
Pharmaceutical Drugs ◽  
Negative Effects ◽  
Anti Inflammatory ◽  
Experimental Expression

Rheumatoid arthritis, caused by abnormalities in the autoimmune system, affects about 1% of the population. Rheumatoid arthritis does not yet have a proper treatment, and current treatment has various side effects. Therefore, there is a need for a therapeutic agent that can effectively treat rheumatoid arthritis without side effects. Recently, research on pharmaceutical drugs based on peptides has been actively conducted to reduce negative effects. Because peptide drugs are bio-friendly and bio-specific, they are characterized by no side effects. Truncated-IK (tIK) protein, a fragment of IK protein, has anti-inflammatory effects, including anti-rheumatoid arthritis activity. This study focused on the fact that tIK protein phosphorylates the interleukin 10 receptor. Through homology modeling with interleukin 10, short tIK epitopes were proposed to find the essential region of the sequence for anti-inflammatory activity. TH17 differentiation experiments were also performed with the proposed epitope. A peptide composed of 18 amino acids with an anti-inflammatory effect was named tIK-18mer. Additionally, a tIK 9-mer and a 14-mer were also found. The procedure for the experimental expression of the proposed tIK series (9-mer, 14-mer, and 18-mer) using bacterial strain is discussed.

Fenbufen, a New Non-Steroidal Anti-Inflammatory Agent in Rheumatoid Arthritis, its Efficacy and Toxicity

1980 ◽  
Vol 8 (5) ◽  
pp. 333-338 ◽  
Author(s):  
Alfred Becker ◽  
Rex T Hoffmeister
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Half Life ◽  
Butanoic Acid ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Inflammatory Agent ◽  
Anti Inflammatory ◽  
Mild Toxicity

Fenbufen, a new butanoic acid derivative with anti-inflammatory properties, was evaluated in an open-label study. It was found that fenbufen was an effective anti-inflammatory agent with tolerable and acceptable potential side-effects. Its advantages appeared to be its long clinical half-life and relatively mild toxicity and/or allergic response.

A Double Blind Cross over Study of Ibuprofen, Metiazinic Acid, Aspirin and a Placebo in Rheumatoid Arthritis

1972 ◽  
Vol 1 (1) ◽  
pp. 18-21 ◽  
Author(s):  
T Hadidi ◽  
D K Asar ◽  
A Esmat
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Knee Score ◽  
Subjective Improvement ◽  
Double Blind ◽  
Erythrocyte Sedimentation ◽  
Before And After ◽  
Anti Inflammatory ◽  
Articular Index ◽  
Inflammatory Action

In a double-blind cross-over study the analgesic and anti-inflammatory action of ibuprofen 1600 mg/day in cases of rheumatoid arthritis has been compared with aspirin 4 g/day, metiazinic acid 1 .5 g/day and a placebo, lactose. Each compound was administered in identical capsules and in a totally randomised order to all patients studied. Assessment of the articular index, grip strength, knee score, erythrocyte sedimentation rate and subjective improvement was made before and after one week's treatment with each drug. In the doses used in this trial, the analgesic and anti-inflammatory activity of metiazinic acid in rheumatoid arthritis, was found to be approximately equipotent to that of aspirin, while ibuprofen seemed to be slightly more potent and to cause fewer side-effects.

Diftalone: A New Non-Steroidal Anti-Inflammatory Agent: Comparative Study with Phenylbutazone in the Treatment of Rheumatoid Arthritis

1977 ◽  
Vol 5 (1) ◽  
pp. 18-25 ◽  
Author(s):  
F Chalem ◽  
P Farias ◽  
H Lizarazo ◽  
P Peña
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Comparative Study ◽  
Clinical Improvement ◽  
Laboratory Tests ◽  
Double Blind Study ◽  
Double Blind ◽  
Treatment Groups ◽  
Inflammatory Agent ◽  
Anti Inflammatory

A double-blind study was carried out to compare the effectiveness and tolerability of diftalone and phenylbutazone in thirty patients with classical or definite rheumatoid arthritis, randomly distributed between the two treatment groups. Both drugs were administered according to a progressively decreasing daily dosage schedule: 1,000 mg during the 1st week; 750 mg the 2nd week and 500 mg from the 3rd week on for diftalone; 400 mg, 300 mg, and 200 mg daily for the 1st, 2nd and from the 3rd week on respectively for phenylbutazone. The study lasted twelve weeks. The clinical controls and laboratory tests were performed weekly up to the 8th week, while the final evaluation was made at the end of the 3rd month. Twelve patients in the group receiving diftalone and fourteen in the phenylbutazone group completed the trial. Clinical improvement was observed in both groups. Effectiveness was somewhat more evident in the diftalone group. Tolerability was acceptable for both drugs, although the diftalone patients showed less frequent and intense side-effects than those treated with phyenylbutazone. No significant differences were found as regards the laboratory parameters, except a significant fall of the E.S.R. (p < 0·05) in the diftalone group. Diftalone seems to be an effective and safe anti-inflammatory agent in the treatment of rheumatoid arthritis.

Flufenamic Acid and Placebo Compared in Rheumatoid Arthritis and Osteoarthritis

1981 ◽  
Vol 9 (4) ◽  
pp. 253-256 ◽  
Author(s):  
G Kagan ◽  
L Huddlestone ◽  
P Wolstencroft
Keyword(s):  
Rheumatoid Arthritis ◽  
General Practice ◽  
Side Effects ◽  
Crossover Study ◽  
Morning Stiffness ◽  
Flufenamic Acid ◽  
Moderate Pain ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Forty patients in general practice with rheumatoid arthritis or osteoarthritis were identified as suffering from moderate pain and tenderness and moderate stiffness in excess of 30 minutes. After discontinuation of non-steroidal anti-inflammatory drugs for 2 weeks, a crossover study was conducted comparing the benefits of flufenamic acid, 100 mg, four times daily with placebo. At the same time, paracetamol at a dose up to 8 × 500 mg daily, could be used for pain which the patient judged to be unrelieved. Thirty-four patients completed the two 3-week test periods and twenty-one patients were improved in relation to morning stiffness and pain by flufenamic acid and twelve patients by placebo – a difference greater than would have occurred by chance (p = 0.05). At the same time, paracetamol consumption was reduced significantly from a mean of 91.29 tablets to 60.68 tablets for each 3-week period. Side-effects occurred in ten patients on placebo and fifteen patients on flufenamic acid. One patient on each medication had to discontinue for multiple side-effects. Diarrhoea occurred in two patients on flufenamic acid and in one patient on placebo. Flufenamic acid is clearly effective and side-effects do not occur more often than would be expected by chance when compared with placebo.

scholarly journals Indomethacin in rheumatoid arthritis: an evaluation of its anti-inflammatory and side effects.

BMJ ◽  
1967 ◽  
Vol 1 (5532) ◽  
pp. 69-75 ◽  
Author(s):  
P. Donnelly ◽  
K. Lloyd ◽  
H. Campbell
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Anti Inflammatory

scholarly journals The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids

2019 ◽  
Vol 116 (28) ◽  
pp. 14200-14209 ◽  
Author(s):  
Guoqiang Hua ◽  
Naimah Zein ◽  
Laetitia Paulen ◽  
Pierre Chambon
Keyword(s):  
Rheumatoid Arthritis ◽  
Type 2 Diabetes ◽  
Side Effects ◽  
Fatty Liver ◽  
Skin Atrophy ◽  
Bona Fide ◽  
Anti Inflammatory ◽  
Synthetic Glucocorticoids

Seventy years after the discovery of their anti-inflammatory properties, glucocorticoids (GCs) remain the mainstay treatment for major allergic and inflammatory disorders, such as atopic dermatitis, asthma, rheumatoid arthritis, colitis, and conjunctivitis, among others. However, their long-term therapeutical administration is limited by major debilitating side effects, e.g., skin atrophy, osteoporosis, Addison-like adrenal insufficiency, fatty liver, and type 2 diabetes syndrome, as well as growth inhibition in children. These undesirable side effects are mostly related to GC-induced activation of both the direct transactivation and the direct transrepression functions of the GC receptor (GR), whereas the activation of its GC-induced indirect tethered transrepression function results in beneficial anti-inflammatory effects. We have reported in the accompanying paper that the nonsteroidal compound CpdX as well as its deuterated form CpdX-D3 selectively activate the GR indirect transrepression function and are as effective as synthetic GCs at repressing inflammations generated in several mouse models of major pathologies. We now demonstrate that these CpdX compounds are bona fide selective GC receptor agonistic modulators (SEGRAMs) as none of the known GC-induced debilitating side effects were observed in the mouse upon 3-mo CpdX treatments. We notably report that, unlike that of GCs, the administration of CpdX to ovariectomized (OVX) mice does not induce a fatty liver nor type 2 diabetes, which indicates that CpdX could be used in postmenopausal women as an efficient “harmless” GC substitute.

Mefenamic Acid Compared with Ibuprofen in the Treatment of Rheumatoid Arthritis

1977 ◽  
Vol 5 (3) ◽  
pp. 161-163 ◽  
Author(s):  
R D G Leslie
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Mefenamic Acid ◽  
Double Blind ◽  
Patient Study ◽  
Anti Inflammatory ◽  
Inflammatory Effect

A randomized double-blind within-patient study of mefenamic acid compared with ibuprofen was performed on forty patients with rheumatoid arthritis. It was concluded that mefenamic acid and ibuprofen had an analgesic and anti-inflammatory effect which was not significantly different in the dosages employed. Apart from six complaints of drowsiness on ibuprofen with two complaints on mefenamic acid, the side-effects were similar.

Sign in / Sign up

Export Citation Format

Share Document